Volume 23 -
yafte 2021, 23 - : 62-72 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Noorazar L, Mehdizadeh M, Farhadi hosseinabadi B, Parkhideh S, Hajifathali A. The Mechanism of Treatment Failure in AML. yafte 2021; 23 :62-72
URL: http://yafte.lums.ac.ir/article-1-3325-en.html
URL: http://yafte.lums.ac.ir/article-1-3325-en.html
Leila Noorazar 
, Mahshid Mehdizadeh , Behrouz Farhadi hosseinabadi , Sayeh Parkhideh , Abbas Hajifathali *
, Mahshid Mehdizadeh , Behrouz Farhadi hosseinabadi , Sayeh Parkhideh , Abbas Hajifathali *
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (1146 Views)
Background: Acute myeloblastic leukemia (AML) is one of the most common types of blood malignancies and has a high mortality rate in the world. Cytogenetic abnormalities are one of the several risk factors that have been suggested for this disease. With advances in the design and use of various drugs for AML treatment, leukemic cells using various mechanisms can become resistant to the cytotoxicity of drugs. Indeed, these factors result in cancer survival and treatment failure. On the other hand, predicting prognosis and relapse of the disease depends on drug resistance of leukemic cells and choosing of treatment process. Our aim in this review article is to investigate the most common ways of AML treatment failure. By knowing these factors, more effective drugs are produced and new therapeutic protocoles are used in the treatment of AML.
Type of Study: Review article |
Subject:
داخلی
Received: 2021/05/27 | Accepted: 2021/11/8 | Published: 2021/11/15
Received: 2021/05/27 | Accepted: 2021/11/8 | Published: 2021/11/15
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
